Assessing the Likely Cost-Utility of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin as Induction Therapy for High-Risk Kidney Transplant Recipients
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1709
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2014
Authors
Publisher
Elsevier BV